Autolus raises FY2026 AUCATZYL revenue guidance to $140-150M, secures up to $250M credit facility

Autolus Therapeutics plc

Preliminary Q2 2026 AUCATZYL net product revenue ~$45M, up ~70% QoQ and >100% YoY.
FY2026 net product revenue guidance raised to $140-150M from $120-135M.
Gross margin improved to ~35% in H1 2026 from negative ~20% in H2 2025.
Entered five-year interest-only credit facility with Perceptive Advisors for up to $250M; initial $75M funded.
Cash runway extended into Q2 2028; additional $150M available upon revenue milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.